ArticleOncology letters2026
Identification and validation of aging-related genes in patients with multiple myeloma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify and validate aging-related genes (ARGs) implicated in multiple myeloma (MM), thereby advancing the understanding of the molecular mechanisms underlying the disease. mRNA expression data were retrieved from the Gene Expression Omnibus, and used as a training set to identify ARGs. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were conducted to explore the functional roles of the ARGs in MM. Candidate genes identified through least absolute shrinkage and selection operator (LASSO) logistic regression and support vector machine recursive feature elimination (SVM-RFE) were compared using a Venn diagram, which revealed the overlap between the genes identified by the two algorithms. A receiver operating characteristic curve was generated based on the screening results. The candidate genes were further validated using the GSE39754 and GSE5900 datasets. Real-time quantitative polymerase chain reaction (RT-qPCR) was employed to validate the mRNA expression of key genes. Compared to normal individuals, patients with MM exhibited differential expression of 19 genes, of which 5 were upregulated and 14 downregulated. A total of 6 candidate genes (TXN, JUN, FOS, HIF1A, CAT and KCNA3) were identified through LASSO regression and SVM-RFE screening. Among them, TXN exhibited the most significant differential expression, suggesting its potential as a diagnostic biomarker for MM. In addition,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.